Medroxyprogesterone acetate and immunoreactive medroxyprogesterone acetate metabolites measured by two different selective radioimmunoassay antibodies in medroxyprogesterone acetate treated breast cancer patients
Sturm, G.; Antal, E.; Schmidt Rhode, P.; Bauer, T.; Schulz K D.
Anticancer Research 6(3 Part A): 362
1986
ISSN/ISBN: 0250-7005 Document Number: 510666
Document emailed within 1 workday
Related Documents
Zia, Y.; Tang, J.H.; Chinula, L.; Tegha, G.; Stanczyk, F.Z.; Kourtis, A.P. 2019: Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi Contraception 100(5): 402-405Sica, G.; Iacopino, F.; Marini, L.; Robustelli della Cuna, G. 1992: Antiproliferative effect of leuprorelin acetate, alone or combined with tamoxifen or medroxyprogesterone acetate, on human breast cancer cell lines Clinical Therapeutics 14 Suppl A: 87-96
Mantovani, G.; Macciò, A.; Lai, P.; Massa, E.; Ghiani, M.; Santona, M.C. 1998: Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate Seminars in Oncology 25(2 Suppl 6: 45-52
Cooper, A.J.; Sandhu, S.; Losztyn, S.; Cernovsky, Z. 1992: A double-blind placebo controlled trial of medroxyprogesterone acetate and cyproterone acetate with seven pedophiles Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 37(10): 687-693
Africander, D.J.; Storbeck, K.-H.; Hapgood, J.P. 2014: A comparative study of the androgenic properties of progesterone and the progestins, medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A) Journal of Steroid Biochemistry and Molecular Biology 143: 404-415
Tomasicchio, M.; Avenant, C.; Du Toit, A.; Ray, R.M.; Hapgood, J.P. 2013: The progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor PLOS one 8(5): E62895
Kaunitz, A.M. 1996: Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer Journal of Reproductive Medicine 41(5 Suppl): 419-427
Lorenz, I.; Mechl, Z. 1985: Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer Neoplasma 32(1): 119-124
Govender, Y.; Avenant, C.; Verhoog, N.J.D.; Ray, R.M.; Grantham, N.J.; Africander, D.; Hapgood, J.P. 2014: The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor Plos one 9(5): E96497
Africander, D.; Louw, R.; Verhoog, N.; Noeth, D.; Hapgood, J.P. 2011: Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract Contraception 84(4): 423-435
Iba, T.; Kidokoro, A.; Fukunaga, M.; Sugiyama, K.; Aihara, N.; Suda, M. 2001: The efficacy of combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR), cyclophosphamide (CPA) and medroxyprogesterone acetate (MPA) for bone metastasis in breast cancer patients Gan to Kagaku Ryoho. Cancer and ChemoTherapy 28(7): 973-977
Pannuti, F.; Di Marco, A.R.; Martoni, A.; Fruet, F.; Strocchi, E.; Burroni, P.; Marraro, D. 1982: Medroxyprogesterone acetate (MAP) in high doses in the treatment of breast cancer in advanced stages Minerva Ginecologica 34(11): 977-979
Møller, K.A.; Andersen, A.P. 1981: Peroral administration of medroxyprogesterone acetate (MPA) in advanced cancer of the breast. A preliminary report Acta obstetricia et gynecologica Scandinavica. Supplement 101: 47-48
Sica, G.; Lama, G.; Iacopino, F.; Angelucći, C.; Della Cuna, G.R.; Marchetti, P. 1991: Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells Anticancer Research 11(6): 2099-2102
Klaassen, D.J.; Rapp, E.F.; Hirte, W.E. 1976: Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women Cancer Treatment Reports 60(3): 251-253
Toi, M.; Taniguchi, T.; Hayashi, K.; Tominaga, T. 1995: The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(6): 799-804
Guarnieri, A.; Tucci, E.; D'Aniello, C.; Carli, A.; Mariani, L.; De Stefano, A.; Nardi, P. 1984: Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 3(5): 320-323
Takatsuka, Y.; Katoh, T.; Tsumura, I.; Kobayakawa, K.; Kawahara, T. 1992: Successful treatment of disseminated breast cancer with combination therapy of 5'-deoxy-5'-fluorouridine (5'-DFUR), medroxyprogesterone acetate (MPA) and cyclophosphamide (CPA) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(1): 107-110
Pannuti, F.; Camaggi, C.M.; Strocchi, E.; Giovannini, M.; Di Marco, A.R.; Costanti, B. 1982: Medroxyprogesterone acetate (MAP) relative bioavailability after single high-dose administration in cancer patients Cancer Treatment Reports 66(12): 2043-2049
Kihara, M.; Kontani, K.; Yamauchi, A.; Yokomise, H. 2005: Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(5): 683-686